<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35747023</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Post COVID-19 Chronic Parenchymal Lung Changes.</ArticleTitle><Pagination><StartPage>e25197</StartPage><MedlinePgn>e25197</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e25197</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.25197</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Persistent parenchymal lung changes are an important long-term sequela of COVID-19. There are limited data on this COVID-19 infection sequela characteristics and trajectories. This study aims to evaluate persistent COVID-19-related parenchymal lung changes 10 weeks after acute viral pneumonia and to identify associated risk factors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a retrospective case-control observational study involving 38 COVID-19 confirmed cases using nasopharyngeal swab reverse transcriptase-polymerase chain reaction (RT-PCR) at King Abdullah Medical City (KAMC) Hospital, Makkah. Patients were recruited from the post-COVID-19 interstitial lung disease (ILD) clinic. Referral to this clinic was based on the pulmonology consultant's assessment of hospitalized patients suspected of developing COVID-19-related ILD changes during hospitalization.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-eight patients with parenchymal lung changes were evaluated at the ILD clinic. Nineteen patients who had persistent parenchymal changes 10 weeks after the acute illness (group 1) were compared with 19 control patients who had accelerated clinical and/or radiological improvement (group 2). Group 1 was found to have the more severe clinical and radiological disease, with a higher peak value of inflammatory biomarkers. Two risk factors were identified, neutrophil-lymphocyte ratio (NLR) &gt; 3.13 at admission increases the odds ratio (OR) of chronic parenchymal changes by 6.42 and 5.92 in the univariate and multivariate analyses, respectively. Invasive mechanical ventilation had a more profound effect with ORs of 13.09 and 44.5 in the univariate and multivariate analyses, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Herein, we found that only receiving invasive mechanical ventilation and having NLR &gt;3.13 at admission were strong risk factors for persistent parenchymal lung changes. Neither the clinical severity of the acute illness nor the radiological one is found to predict this outcome. None of the medications received during the acute illness were found to alter the risk for this post-COVID-19 infection sequelae.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022, Touman et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Touman</LastName><ForeName>Abdelfattah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, King Abdullah Medical City, Makkah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahyat</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, King Abdullah Medical City, Makkah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bulkhi</LastName><ForeName>Adeeb</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Umm Al-Qura University, Makkah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khairo</LastName><ForeName>Mutaz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology, King Abdullah Medical City, Makkah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alyamani</LastName><ForeName>Wael</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Radiology, King Abdullah Medical City, Makkah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldobyany</LastName><ForeName>Ahmad M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, King Abdullah Medical City, Makkah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaleb</LastName><ForeName>Nabil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, King Abdullah Medical City, Makkah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashi</LastName><ForeName>Hadeel</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, King Abdullah Medical City, Makkah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsobaie</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, King Abdullah Medical City, Makkah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alqurashi</LastName><ForeName>Eid</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, King Abdullah Medical City, Makkah, SAU.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">complication</Keyword><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">interstitial lung disease</Keyword><Keyword MajorTopicYN="N">long covid</Keyword><Keyword MajorTopicYN="N">post-covid-19 fibrosis</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>2</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35747023</ArticleId><ArticleId IdType="pmc">PMC9209776</ArticleId><ArticleId IdType="doi">10.7759/cureus.25197</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO COVID-19 Dashboard.  [
May;
2021 
];https://covid19.who.int/ 2020 </Citation></Reference><Reference><Citation>Treatment Guidelines.  [
May;
2021 
];https://www.covid19treatmentguidelines.nih.gov/ 2020 </Citation></Reference><Reference><Citation>More than 50 long-term effects of COVID-19: a systematic review and meta-analysis [PREPRINT] Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. medRxiv. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Post-acute COVID-19 syndrome. Nalbandian A, Sehgal K, Gupta A, et al. Nat Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Yu M, Liu Y, Xu D, Zhang R, Lan L, Xu H. Korean J Radiol. 2020;21:746&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7231610</ArticleId><ArticleId IdType="pubmed">32410413</ArticleId></ArticleIdList></Reference><Reference><Citation>Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. Wang Y, Dong C, Hu Y, et al. Radiology. 2020;296:0&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233482</ArticleId><ArticleId IdType="pubmed">32191587</ArticleId></ArticleIdList></Reference><Reference><Citation>Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19) Pan F, Ye T, Sun P, et al. Radiology. 2020;295:715&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233367</ArticleId><ArticleId IdType="pubmed">32053470</ArticleId></ArticleIdList></Reference><Reference><Citation>CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19) Li K, Fang Y, Li W, et al. Eur Radiol. 2020;30:4407&#x2013;4416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095246</ArticleId><ArticleId IdType="pubmed">32215691</ArticleId></ArticleIdList></Reference><Reference><Citation>Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis. Ahmed H, Patel K, Greenwood DC, et al. J Rehabil Med. 2020;52:0.</Citation><ArticleIdList><ArticleId IdType="pubmed">32449782</ArticleId></ArticleIdList></Reference><Reference><Citation>Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Hui DS, Joynt GM, Wong KT, et al. Thorax. 2005;60:401&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1758905</ArticleId><ArticleId IdType="pubmed">15860716</ArticleId></ArticleIdList></Reference><Reference><Citation>Dynamic changes of serum SARS-coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge. Xie L, Liu Y, Fan B, et al. Respir Res. 2005;6:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC545044</ArticleId><ArticleId IdType="pubmed">15638943</ArticleId></ArticleIdList></Reference><Reference><Citation>Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Das KM, Lee EY, Singh R, et al. Indian J Radiol Imaging. 2017;27:342&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5644332</ArticleId><ArticleId IdType="pubmed">29089687</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Sonnweber T, Sahanic S, Pizzini A, et al. Eur Respir J. 2021;57:2003481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736754</ArticleId><ArticleId IdType="pubmed">33303539</ArticleId></ArticleIdList></Reference><Reference><Citation>Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection. Trinkmann F, M&#xfc;ller M, Reif A, et al. Eur Respir J. 2021;57:2003002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821834</ArticleId><ArticleId IdType="pubmed">33479105</ArticleId></ArticleIdList></Reference><Reference><Citation>Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up. Qin W, Chen S, Zhang Y, et al. Eur Respir J. 2021;58:2003677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7877322</ArticleId><ArticleId IdType="pubmed">33574077</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyspnoea, lung function and CT findings 3&#x2005;months after hospital admission for COVID-19. Lerum TV, Aal&#xf8;kken TM, Br&#xf8;nstad E, et al. Eur Respir J. 2021;57:2003448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736755</ArticleId><ArticleId IdType="pubmed">33303540</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. Xu J, Xu X, Jiang L, Dua K, Hansbro PM, Liu G. Respir Res. 2020;21:182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359430</ArticleId><ArticleId IdType="pubmed">32664949</ArticleId></ArticleIdList></Reference><Reference><Citation>Is progression of pulmonary fibrosis due to ventilation-induced lung injury? Albert RK, Smith B, Perlman CE, Schwartz DA. Am J Respir Crit Care Med. 2019;200:140&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6635778</ArticleId><ArticleId IdType="pubmed">31022350</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. Guler SA, Ebner L, Aubry-Beigelman C, et al. Eur Respir J. 2021;57:2003690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8082329</ArticleId><ArticleId IdType="pubmed">33419891</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulm Med. 2020;2020:6175964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7439160</ArticleId><ArticleId IdType="pubmed">32850151</ArticleId></ArticleIdList></Reference><Reference><Citation>Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Myall KJ, Mukherjee B, Castanheira AM, et al. Ann Am Thorac Soc. 2021;18:799&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8086530</ArticleId><ArticleId IdType="pubmed">33433263</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechanical ventilation-associated lung fibrosis in acute respiratory distress syndrome: a significant contributor to poor outcome. Cabrera-Benitez NE, Laffey JG, Parotto M, Spieth PM, Villar J, Zhang H, Slutsky AS. Anesthesiology. 2014;121:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4991945</ArticleId><ArticleId IdType="pubmed">24732023</ArticleId></ArticleIdList></Reference><Reference><Citation>Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. Liu J, Liu Y, Xiang P, et al. J Transl Med. 2020;18:206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237880</ArticleId><ArticleId IdType="pubmed">32434518</ArticleId></ArticleIdList></Reference><Reference><Citation>Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with idiopathic pulmonary fibrosis. Karampitsakos T, Torrisi S, Antoniou K, et al. Respir Res. 2021;22:140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8097815</ArticleId><ArticleId IdType="pubmed">33952261</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>